DelveInsight’s, “Multiple Myeloma Pipeline Insights, 2023,” report provides comprehensive insights about 100+ companies and 130+ pipeline drugs in Multiple Myeloma pipeline landscape. It covers the Multiple Myeloma pipeline drug profiles, including Multiple Myeloma clinical trials and nonclinical stage products. It also covers the Multiple Myeloma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Multiple Myeloma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Multiple Myeloma NDA approvals (if any), and product development activities comprising the technology, Multiple myeloma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Multiple Myeloma Pipeline Report
- DelveInsight’s Multiple Myeloma pipeline report depicts a robust space with 100+ active players working to develop 130+ pipeline therapies for Multiple Myeloma treatment.
- The leading Multiple Myeloma Companies includes NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, Lava Therapeutics, Prelude Therapeutics, Amgen, Pfizer, Rapa Therapeutics, Arcellx, Inc., Gilead Sciences, Novartis, Celgene Corporation, Genmab, Harpoon Therapeutics, Cytovia Therapeutics, Ichnos Sciences, Poseida Therapeutics, Allogene Therapeutics, Seagen Inc., Regeneron Pharmaceuticals, CFT7455, C4 Therapeutics, CARsgenTherapeutics Co.,Ltd, CELLECTAR BIOSCIENCES, INC., Nektar Therapeutics, iTeos Therapeutics, CASI Pharmaceuticals, Fate Therapeutics, Actinium Pharmaceuticals, Inc., Molecular Templates, Inc., NexImmune, Inc., LAVA Therapeutics, Sorrento Therapeutics, Chimerix, Ascentage Pharma Group Inc., Keymed Biosciences, MiNK Therapeutics, and others.
- Promising Multiple Myeloma Pipeline Therapies includes NEXI 002, AMG-701, ABBV 453, ALLO-605, PBCAR269A, TAK-981, ABBV-383, ORIC-533, agenT-797, ION251, UCARTCS1A, Y150, Talquetamab, Ipilimumab, LAVA-051, Felzartamab, Elranatamab, RAPA-201, CART-ddBCMA, Magrolimab, PHE885, Marizomib, Teclistamab, HPN-217, CYT-338, ISB 1342, P-BCMA-ALLO1, ALLO-715, ALLO-605, SEA-BCMA, REGN5458, NKTR-255, Iopofosine, EOS-448, CID-103, FT538, MT-0169, NEXI-002, LAVA-051, STI-6129, ONC201, APG-2575, CM336, agenT-797, and others.
- The Multiple Myeloma companies and academics are working to assess challenges and seek opportunities that could influence R&D Multiple myeloma. The Multiple Myeloma pipeline therapies under development are focused on novel approaches to treat/improve Multiple myeloma.
To explore more information on the latest breakthroughs in the Multiple Myeloma Pipeline treatment landscape of the report, click here @ Multiple Myeloma Pipeline Outlook
Multiple Myeloma Overview
Multiple myeloma is a clonal plasma cell proliferative disorder characterized by the abnormal increase of monoclonal paraprotein leading to evidence of specific end-organ damage. Unchecked, the excess production of these plasma cells can ultimately lead to specific end-organ damage. Most commonly, this is seen when at least one of the following clinical manifestations are present: hypercalcemia, renal dysfunction, anemia, or bone pain accompanied by lytic lesions.
Recent Developments Activities in the Multiple Myeloma Treatment Landscape
- In August 2022, Ipsen announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. Epizyme now operates as ‘an Ipsen company’ at deal close.
- In June 2022, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for talquetamab for the treatment of adult patients with relapsed or refractory multiple myeloma.
- In June 2021, AbbVie and Teneobio, Inc. announced that AbbVie exercised its exclusive right to acquire TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma (R/R MM).
For further information, refer to the detailed Multiple Myeloma Unmet Needs, Multiple Myeloma Market Drivers, and Multiple Myeloma Market Barriers, click here for Multiple Myeloma Ongoing Clinical Trial Analysis
Multiple myeloma Emerging Drugs Profile
Elranatamab: Pfizer
Elranatamab is an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody. Binding affinity to BCMA and CD3 has been optimized, to potentially elicit potent T-cell-mediated anti-myeloma activity. Elranatamab is being investigated as a fixed dose subcutaneous administration, which is intended to allow higher doses than intravenous administration without increasing adverse events. Elranatamab has been granted Orphan Drug Designations by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of MM. The FDA and EMA have also granted elranatamab Fast Track Designation and the PRIME scheme, respectively, for the treatment of patients with MM who are refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 antibody.
Felzartamab: Janssen Pharmaceutical
Felzartamab (MOR202) is a therapeutic human monoclonal antibody derived from MorphoSys’ HuCAL antibody library and directed against CD38. In Membranous Nephropathy, long-lived plasma cells drive pathogenic antibody production, contributing to functional damage to the glomeruli in the kidney. By targeting CD38, felzartamab has the potential to deplete the CD38 positive plasma cells, which may ultimately improve clinical outcomes in a broad range of autoantibody driven diseases. MorphoSys is currently evaluating the safety and efficacy of investigational felzartamab for patients with anti-PLA2R antibody-positive membranous nephropathy (M-PLACE and NewPLACE trial) and Immunoglobulin A Nephropathy (IGNAZ trial)
Multiple Myeloma Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies Multiple myeloma. The companies which have their Multiple myeloma drug candidates in the most advanced stage, i.e phase III include Janssen Pharmaceuticals.
Request a sample and discover the recent advances in Multiple Myeloma Ongoing Clinical Trial Analysis and Medications, click here @ Multiple Myeloma Treatment Landscape
Scope of the Multiple Myeloma Pipeline Report
- Coverage- Global
- Multiple MyelomaCompanies- NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, Lava Therapeutics, Prelude Therapeutics, Amgen, Pfizer, Rapa Therapeutics, Arcellx, Inc., Gilead Sciences, Novartis, Celgene Corporation, Genmab, Harpoon Therapeutics, Cytovia Therapeutics, Ichnos Sciences, Poseida Therapeutics, Allogene Therapeutics, Seagen Inc., Regeneron Pharmaceuticals, CFT7455, C4 Therapeutics, CARsgenTherapeutics Co.,Ltd, CELLECTAR BIOSCIENCES, INC., Nektar Therapeutics, iTeos Therapeutics, CASI Pharmaceuticals, Fate Therapeutics, Actinium Pharmaceuticals, Inc., Molecular Templates, Inc., NexImmune, Inc., LAVA Therapeutics, Sorrento Therapeutics, Chimerix, Ascentage Pharma Group Inc., Keymed Biosciences, MiNK Therapeutics, and others.
- Multiple MyelomaPipeline Therapies- NEXI 002, AMG-701, ABBV 453, ALLO-605, PBCAR269A, TAK-981, ABBV-383, ORIC-533, agenT-797, ION251, UCARTCS1A, Y150, Talquetamab, Ipilimumab, LAVA-051, Felzartamab, Elranatamab, RAPA-201, CART-ddBCMA, Magrolimab, PHE885, Marizomib, Teclistamab, HPN-217, CYT-338, ISB 1342, P-BCMA-ALLO1, ALLO-715, ALLO-605, SEA-BCMA, REGN5458, NKTR-255, Iopofosine, EOS-448, CID-103, FT538, MT-0169, NEXI-002, LAVA-051, STI-6129, ONC201, APG-2575, CM336, agenT-797, and others
- Multiple Myeloma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Multiple Myeloma Market Drivers and Multiple Myeloma Market Barriers, click here @ Multiple Myeloma Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Multiple myeloma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Multiple myeloma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Venetoclax: AbbVie
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- PHE885: Novartis
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- ONC 201: Oncoceutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- TNB 383B: TeneoBio
- Drug profiles in the detailed report…..
- Inactive Products
- Multiple myeloma Key Companies
- Multiple myeloma Key Products
- Multiple myeloma- Unmet Needs
- Multiple myeloma- Market Drivers and Barriers
- Multiple myeloma- Future Perspectives and Conclusion
- Multiple myeloma Analyst Views
- Multiple myeloma Key Companies
- Appendix
Got Queries? Find out the related information on Multiple Myeloma Mergers and acquisitions, Multiple Myeloma Licensing Activities @ Multiple Myeloma Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
